Research programme: respiratory syncytial virus vaccine - ID Biomedical

Drug Profile

Research programme: respiratory syncytial virus vaccine - ID Biomedical

Alternative Names: Respiratory syncytial virus vaccine research programme - ID Biomedical

Latest Information Update: 18 Apr 2011

Price : $50

At a glance

  • Originator ID Biomedical Corporation
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Respiratory syncytial virus infections

Most Recent Events

  • 08 Dec 2005 ID Biomedical Corporation has been acquired by GlaxoSmithKline
  • 25 Jun 2003 Preclinical trials in Respiratory syncytial virus infections in Canada (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top